Use access key #2 to skip to page content.
$19.90 -1.06 (-5.06%)
10/6/2008 4:00 PM

Rigel Pharmaceuticals, Inc. (RIGL)

CAPS Rating:
*

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.

X

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating RIGL

Add Stock to Watchlist

What the Community Thinks

Total Members

67 Outperforms
101 Underperforms
 

All-Stars

12 Outperforms
46 Underperforms
 

Wall Street

7 Outperforms
0 Underperforms
 

Members bullish on RIGL are also bullish on:

Members bearish on RIGL are also bearish on:

Ticker Tags

Biotechnology (295), Drug Manufacturers - Major (27), Small Cap (1922)
Suggest a tag

Rigel Pharmaceuticals, Inc. At A Glance

Current Price: $19.90
Last Trade Time: 10/6/2008 4:00 PM
Open: $20.71
Previous Close: $20.96
Daily Range: $17.61 - $20.71
52-Week Range: $6.64 - $31.00
Volume: 769,318
Market Cap: $766.72M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

RIGL VS S&P 500 (SPY)

RIGL 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for RIGL

More Headlines...

Top Bull Pitch

Recs

1

Rigel Pharmaceuticals, Inc. (RIGL)

Avatar imaphule2 (95.20) Submitted: 6/27/08 4:05 PM

Buyout candidate in a major way. Why? NHL drug showed 60% effectiveness in PII trial - yes it was small but that is so statistically significant it is unlikely to go away completely. Assuming 8,000 new potential patients per year we have a drug that will bring in 500M at its peak, maybe more (dep...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Rigel Pharmaceuticals, Inc. (RIGL)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 19 :   1 2 3 4 Next »

Recs

0

 (RIGL)

Avatar pjani06 (21.90) Submitted: 8/22/08 1:11 PM : Underperform Start Price: $22.54 RIGL Score: -7.24

Dont mind shorting this baby, id rather own a basket of other biotech stocks with my extra funds from shorting.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (RIGL)

Avatar imaphule2 (95.20) Submitted: 6/27/08 4:05 PM : Outperform Start Price: $23.25 RIGL Score: 3.73

Buyout candidate in a major way. Why? NHL drug showed 60% effectiveness in PII trial - yes it was small but that is so statistically significant it is unlikely to go away completely. Assuming 8,000 new potential patients per year we have a drug that will bring in 500M at its peak, maybe more (depends on additional applications). Soooo... why a buyout? The cost of bringing a drug to market is approx 1.2B. They don't have that kind of $. More importantly, given the cost of getting a FDA approved manufacturing facility up and running is also a B. Should the get approval and not at least partner it they will be a victim of their own success. They (probably) know this. They need a company with deep pockets to fund their clinical trial for NHL as well as the rest of their (for their size) respectable pipeline. Looking at past deals for similar companies in this situation I would estimate the buyout at 2-3B. The only real questions are when and who.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (RIGL)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM : Underperform Start Price: $22.85 RIGL Score: -5.92

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (RIGL)

Avatar Gemini846 (24.16) Submitted: 6/25/08 9:44 AM : Underperform Start Price: $23.07 RIGL Score: -7.05

Pharma - MSN DDD

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (RIGL)

Avatar hansthered0 (< 20) Submitted: 6/21/08 10:18 PM : Underperform Start Price: $23.65 RIGL Score: -4.86

From what I can tell this company has never made a dime...Even if they make it big with their clinical trials..I just don't think they're going to know how to handle it.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 19 :   1 2 3 4 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE

Top
Pick		Member NameMember RatingStart
Date		CallTime FrameStart
Price		Stock
Gain		S&P
Gain		ScorePitch
TrackRBCCapMkts 78.29 09/03/08 Outperform NS $23.35-14.78%-18.13%+3.35
TrackCitigroup < 20 08/27/08 Outperform NS $22.40-11.16%-17.91%+6.74
TrackStanfordRes 45.12 07/22/08 Outperform NS $24.58-19.04%-16.32%-2.72
TrackFortisBank 98.30 01/07/08 Outperform NS $24.19-17.73%-26.15%+8.42
TrackLehmanBros 43.99 12/14/07 Outperform NS $27.33-27.19%-29.21%+2.02
TrackCreditSuiss 66.77 07/19/07 Outperform NS $8.76+127.17%-32.53%+159.69
TrackJefferies < 20 06/08/07 Outperform NS $9.50+109.47%-29.95%+139.43

Results 1 - 7 of 7  

X

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners